KCT0004206
Not yet recruiting
Not Applicable
Analysis of Prognostic factors and Biomarkers for the prediction of systemic therapies including tyrosine kinase inhibitors and immunotherapy response in patients with locally advanced hepatocellular carcinoma
ConditionsNeoplasms
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Seoul National University Hospital
- Enrollment
- 400
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with histologically confirmed locally advanced or metastatic HCC, which was judged not to be eligible for surgical resection, liver transplantation or radiofrequency ablation
Exclusion Criteria
- •Patients with histologically confirmed fibrolamellar type HCC or combined type with cholangiocarcinoma
- •Patients who refuse to participate in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Exploration of predictive and prognostic factor in gastrointestinal cancerGastric cancer, Colorectal cancerJPRN-UMIN000030793Kanagawa Cancer Center2,500
Completed
Not Applicable
Prospective investigation of prognostic factors for failure of glaucoma surgeries.glaucomaJPRN-UMIN000006008Kumamoto University300
Recruiting
Phase 3
Determining factors of prognosis and morbidity in Chronic Chagas Heart Disease - phase IIIRBR-9gm9bzniversidade Federal de Minas Gerais
Completed
Not Applicable
Analysis of risk factors and prognostic factors included histological status of underlying liver disease of patients undergoing curative resection or radiofrequency ablation of hepatocellular carcinoma; May hepatic steatosis correlate with the postoperative recurrence of hepatocellular carcinoma?Patients with Hepatocellular carcinoma(HCC) after curative treatmentJPRN-UMIN000000970Department of Internal Medicine, National Hospital Organization IwakuniClinical Center400
Unknown
Not Applicable
Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in ramucirumab plus paclitaxel therapy for elderly patients with unresectable or recurrent gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000021743Tohoku Clinical Oncology Research and Education Society (T-CORE)30